Mediavastio
Technology

Cheap, decades-old transplant drug delays full onset of type 1 diabetes

April 04, 2026 • 5 min read • views
Cheap, decades-old transplant drug delays full onset of type 1 diabetes
  1. Health
Cheap, decades-old transplant drug delays full onset of type 1 diabetes

News By Theresa Sullivan Barger published 4 April 2026

A transplant drug that has been used for decades can preserve the function of insulin-producing cells in young children who are newly diagnosed with type 1 diabetes.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

Unrecognizable middle-aged woman preparing an insulin pen to inject herself with a dose. People who develop type 1 diabetes need to inject insulin to stay alive. But a new trial suggests a cheap transplant drug could delay the progression of the disease. (Image credit: Javier Zayas Photography/Getty Images)
  • Copy link
  • Facebook
  • X
  • Whatsapp
  • Reddit
  • Pinterest
  • Flipboard
  • Email
Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Live Science Sign up for the Live Science daily newsletter now

Get the world’s most fascinating discoveries delivered straight to your inbox.

Become a Member in Seconds

Unlock instant access to exclusive member features.

Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.

You are now subscribed

Your newsletter sign-up was successful

Want to add more newsletters?

Daily Newsletter

Delivered Daily

Daily Newsletter

Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.

Signup + Life's Little Mysteries

Once a week

Life's Little Mysteries

Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.

Signup + How It Works

Once a week

How It Works

Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more

Signup + Space.com Newsletter

Delivered daily

Space.com Newsletter

Breaking space news, the latest updates on rocket launches, skywatching events and more!

Signup + Watch This Space

Once a month

Watch This Space

Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.

Signup + Night Sky This Week

Once a week

Night Sky This Week

Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!

Signup +

Join the club

Get full access to premium articles, exclusive features and a growing list of member rewards.

Explore An account already exists for this email address, please log in. Subscribe to our newsletter

An inexpensive drug that's been used for decades in transplant surgeries can delay the progression of type 1 diabetes in those newly diagnosed, new research suggests.

In previous studies, a high dose of the immune-suppressing drug polyclonal antithymocyte globulin (ATG) reduced the loss of insulin-making cells in the pancreas, called beta cells. The new study shows that a much smaller dose is almost as effective at slowing disease progression in type 1 — but with fewer side effects.

You may like
  • A close up of the pancreas, where purple and pink stained cells can be seen with dark dots for their nucleii Scientists cured type 1 diabetes in mice by creating a blended immune system
  • an illustration of sugar molecules in the blood Needle-free insulin? Scientists invent gel that delivers insulin through the skin in animal studies
  • A child wearing a gray shirt and patterned green pants curls up on a bed with his mother, a blond woman with long straight hair, caressing his head Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy

But there's a window of time soon after diagnosis, called the "honeymoon phase," in which beta cells still produce some insulin; this provides an opportunity to keep those remaining beta cells alive longer. A longer honeymoon phase and more residual beta cell function are tied to reduced risk of diabetes complications, such as heart and kidney disease, down the line.

It's this honeymoon phase that the new study was targeting. The study included 117 participants, who were between the ages of 5 and 25 and had been diagnosed with type 1 diabetes within nine weeks of starting the trial. The participants received either a high, intermediate or low dose of ATG: the high dose was equivalent to 2.5 milligrams of ATG per kilogram of body weight; the intermediate dose was 1.5 mg/kg; and the low dose was 0.5 mg/kg of body weight.

The researchers found that the lowest dose preserved beta cell functioning for a year, according to the paper published Sept. 27 in the journal The Lancet.

The trial was designed to help researchers analyze the lowest effective dose in children as young as 5 years old, lead study author Dr. Chantal Mathieu, endocrinologist at the University Hospital Gasthuisberg Leuven in Belgium, told Live Science. That's because the drug's side effects — such as harmful immune reactions — can be especially hard on them, she said.

Sign up for the Live Science daily newsletter nowContact me with news and offers from other Future brandsReceive email from us on behalf of our trusted partners or sponsorsBy submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.

Islets of Langerhans (lightly stained, pink areas - composed of alpha and beta cells, endocrine tissue), and exocrine tissue (darker, surrounding tissue, secretes digestive enzymes)

In type 1 diabetes, the immune system destroys beta cells located found in the islets of Langerhans in the pancreas (shown here). (Image credit: Ed Reschke/Getty Images)

"The ATG worked wonderfully," she said. The beneficial effect "was the biggest in the smallest children."

This was the third study to confirm the effectiveness of ATG to delay beta cell loss, Mathieu added.

Notably, when researchers reviewed the data, they found a similar level of side effects in the intermediate- and high-dose groups, so they dropped the intermediate dose from further study. The biggest difference between the remaining high- and low-dose groups was the incidence of side effects. One of the most common ATG side effects is serum sickness, an immune reaction to foreign proteins that can be triggered by drugs made in the cells of other animals. (ATG is produced in the cells of rabbits and horses.) In the new study, serum sickness impacted 82% of the participants in the high-dose group and just 32% in the low-dose group.

What to read next
  • illustration of a tumor, shown in red, growing on a pancreas, depicted in blue New triple-drug treatment stops pancreatic cancer in its tracks, a mouse study finds
  • A woman wearing a blue tank top and jeans with long dark hair holds the arm of an older tan man wearing a gray shirt and a baseball cap as they walk down the street, their backs to the camera Single protein could dramatically alter trajectory of Alzheimer's disease
  • An illustration of walls of pink vertical finger-like projections covered with green and purple molecules Viruses in the gut may help prevent blood sugar spikes, mouse study hints

Meanwhile, in the low-dose group, 24% had cytokine release syndrome, a runaway inflammatory response that can include fever, nausea, fatigue, headache, and muscle and joint pain. About 33% of the participants who received the higher dose developed the syndrome.

"I think the reason this is somewhat promising is that it's now one of a handful of drugs that show you can delay type 1 diabetes somewhat," Mathieu said. Another benefit of ATG, Mathieu said, is that it's inexpensive and widely available.

Other medications that have been found to delay diabetes are teplizumab-mzwv (brand name Tzield) and baricitinib (Olumiant). Tzield is given as a 14-day infusion, but it's only approved for use in "stage 2" diabetes — at which point the body has been making antibodies to insulin and has some abnormal blood sugar responses, but most of its insulin-making cells are still working. Few people are diagnosed with diabetes in this early stage, which limits the drug's reach.

Meanwhile, baricitinib — a rheumatoid arthritis drug that hasn't yet been tested in children with diabetes — must be taken continuously to prevent disease progression.

Good news for young children

Dr. Jennifer Sherr, an endocrinologist and professor of pediatrics at Yale School of Medicine, who was not involved in the study, said the results were encouraging, especially for families who would find it extremely challenging to take off from work for their child to receive two days of infusions. In the study, those in the low-dose group received an infusion on the first day and a placebo on the second day, but the placebo day wouldn't be necessary if the drug were given outside a clinical trial, she noted.

Sherr also liked that the study included 5- to 11-year-olds. "Those are the kids who lose their beta cells so fast" after diagnosis, Sherr told Live Science. "Their insulin needs go up incredibly."

Sherr hopes that this less-expensive medication could ultimately be approved for use in diabetes to help give "kids a smoother ride," she said.

As for whether ATG is better than other alternatives demonstrated to delay progression, "many people think it's going to take a multi-agent approach," she said. In other words, to really stop T1D in its tracks, people would likely need to get multiple drugs, Sherr said.

It's premature to say one treatment is better than another. "I think what gives us hope for the future is [that] there are lots of things we can consider," Sherr said.

And in a clinical trial set to begin late this year or early next year, researchers will test a next-generation version of ATG made in genetically modified cows in people newly diagnosed with type 1 diabetes.

RELATED STORIES

—We may finally understand how metformin lowers blood sugar, animal study finds

—In a 1st, scientists reversed type 1 diabetes by reprogramming a person's own fat cells

—Scientists identify new 'type 5' diabetes

The new drug, made by SAB BIO and called SAB-142, is grown in a cow that has been gene edited to produce human antibodies, said lead researcher Dr. Michael Haller, chief of pediatric endocrinology at the University of Florida's Diabetes Institute and advisory board member for SAB BIO. . "The cow can then donate blood," from which the human antibodies are harvested, Haller told Live Science in an email.

The hope is that, because the antibodies are made using human genes, they will no longer trigger serum sickness in patients. The human antibodies are also less likely to cause the immune system to produce antibodies that block the drug's action, so in theory, Haller said, "the new drug may be safer and even more effective in type 1 diabetes."

Editor's note: Haller holds stock options in SAB BIO, in addition to being an advisory board member.

Disclaimer

This article is for informational purposes only and is not meant to offer medical advice.

Theresa Sullivan BargerTheresa Sullivan BargerLive Science Contributor

Theresa Sullivan Barger is an award-winning freelance journalist who covers health, science, and the environment. Her stories have appeared in The New York Times, The Boston Globe, Los Angeles Times, AARP, CURE, Discover, Family Circle, Health Central, Next Avenue, IEEE Spectrum, Connecticut Magazine, CT Health Investigative Team, and more. Based in central Connecticut, she is an advanced master gardener who is passionate about gardening for wildlife, especially pollinators and songbirds.

View More

You must confirm your public display name before commenting

Please logout and then login again, you will then be prompted to enter your display name.

Logout Read more A close up of the pancreas, where purple and pink stained cells can be seen with dark dots for their nucleii Health Scientists cured type 1 diabetes in mice by creating a blended immune system    an illustration of sugar molecules in the blood Medicine & Drugs Needle-free insulin? Scientists invent gel that delivers insulin through the skin in animal studies    A child wearing a gray shirt and patterned green pants curls up on a bed with his mother, a blond woman with long straight hair, caressing his head Health Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy    illustration of a tumor, shown in red, growing on a pancreas, depicted in blue Cancer New triple-drug treatment stops pancreatic cancer in its tracks, a mouse study finds    A woman wearing a blue tank top and jeans with long dark hair holds the arm of an older tan man wearing a gray shirt and a baseball cap as they walk down the street, their backs to the camera Alzheimers & Dementia Single protein could dramatically alter trajectory of Alzheimer's disease    An illustration of walls of pink vertical finger-like projections covered with green and purple molecules Immune System Viruses in the gut may help prevent blood sugar spikes, mouse study hints    Latest in Health A 3D modeled map of a T-shaped organ with yellow, purple and green separating out key nerve tracts. Anatomy Scientists mapped all the nerves of the clitoris for the first time    A close up of the pancreas, where purple and pink stained cells can be seen with dark dots for their nucleii Health Scientists cured type 1 diabetes in mice by creating a blended immune system    A 3D illustartion of green and orange cylindrical-shaped bacteria surrounded by webs of blue and white filaments Medicine & Drugs Scientists have discovered an 'Achilles' heel' in deadly superbugs    A close up of a child's eye that's blue. The image has a blue tint Medicine & Drugs Pig semen component could deliver chemotherapy to hard-to-reach eye cancer, mouse study suggests    A mother with dark hair leans over a small dark-haired child wearing a bright blue shirt. The mother presses a white handkerchief to the child's nose. Genetics Are allergies genetic?    A close up shows a white rat with a brown head holding onto a small thread in front of a blue background. Food & Drink A gut microbe linked to the Mediterranean diet boosts muscle strength in mice    Latest in News Four people wearing black long sleeve shirts and tan pants float in a small room Space Exploration 'Trust us; you look amazing': Artemis II crewmembers share first message from space    Two images with a diagonal golden line between them. The left shows the Artemis II rocket blasting off from the launch pad and the right shows a close up of a purple and pink pancreas tissue sample Space Science news this week: Artemis II lifts off, diabetes cured in mice, and smog in China shapes Arctic storms    A 3D modeled map of a T-shaped organ with yellow, purple and green separating out key nerve tracts. Anatomy Scientists mapped all the nerves of the clitoris for the first time    A look into a dark cockpit with three bright white computer screens Space Exploration Artemis II officially leaves Earth's orbit on the way to the moon    An illustration of the Big Bang, with purple, blue and yellow colors spread out from a white glowing light with straight rays coming out in all directions, all over a starry black background. Physics & Mathematics New tweak to Einstein's relativity could transform our understanding of the Big Bang    The Artemis II rocket producing a flame of smoke as it takes off. Space Exploration In photos: Artemis II's historic launch for the moon    LATEST ARTICLES
  1. A large rust colored octopus floats next to a white stony reef. 1Octopus quiz: Are you a sucker for cephalopod science?
  2. 2Science news this week: Artemis II lifts off, diabetes cured in mice, and smog in China shapes Arctic storms
  3. 3I've witnessed nearly 100 rocket launches. Artemis II was like nothing I've ever experienced.
  4. 4Are allergies genetic?
  5. 5'Trust us; you look amazing': Artemis II crewmembers share first message from space

Related Articles